Photo of Hans Arnqvist

Hans Arnqvist

Studies of vascular metabolism and diabetes

The presence and function of insulin and IGF-I receptors is studied in endothelial and vascular smooth muscle cells. Both in human endothelial cells from micro- and macro-vessels and in human vascular smooth muscle cells IGF-I receptors are several fold more abundant than insulin receptors.

We have shown that insulin and IGF-I receptors also occur as hybrid IGF-I/insulin receptors in human endothelial and vascular smooth muscle cells. The physiological and pathophysiological importance of these observations are now investigated.

In clinical studies we have measured circulating IGF-I and other components of the IGF-system in patients with type 1 diabetes. In type 1 diabetic patients with long duration circulating IGF-I is 30-40% lower than in healthy controls and is not related to glycaemic control. The abnormalities in the IGF-system occur even if the patients are normoglycaemic.

We have shown that in patients with residual endogenous insulin secretion the IGF-system is almost normal while abnormalities are found in patients lacking endogenous insulin secretion. The clinical consequences of the abnormalities in the IGF-system are currently under investigation.

Our current view of the IGF-system in diabetes is shown in the figure below. Insulin deficiency in diabetes causes hyperglycaemia but also changes in the IGF-system. The delivery of insulin through the portal vein to the liver regulate growth hormone receptors and thereby IGF-I production as well as production of IGFBP-1.

Our data suggest that subcutaneous insulin treatment which is the routine used today is insufficient and that insulin delivery through the portal vein is needed to normalize the IGF-system. The IGF-I receptor is abundant in vascular cells and these cells respond to low physiological levels of IGF-I. Low circulating IGF-I may therefore be of particular importance for vascular tissue.

Publications

2026

Emma Paulsson, Emilia Gauffin, Hans Arnqvist, Ioana Simona Chisalita (2026) The Risk of Fractures in Patients with Type 1 Diabetes Mellitus Journal of Clinical Medicine, Vol. 15, Article 7468 (Article in journal) https://dx.doi.org/10.3390/jcm15197468
Emma Paulsson, Sergiu Bogdan Catrina, Cecilia Toppe, Edwin van Asseldonk, Hans Arnqvist, Ioana Simona Chisalita (2026) ApoA1 and ApoB Are Associated with Fracture Risk in Patients with Type 1 Diabetes Journal of Clinical Medicine, Vol. 15, Article 3019 (Article in journal) https://dx.doi.org/10.3390/jcm15083019
Katarina Fagher, Katarina Eeg-Olofsson, Hans Arnqvist, Jan Bolinder, Jan W. Eriksson, Soffia Gudbjörnsdottir, Lennarth Nyström, Mona Landin-Olsson (2026) Uric acid and future complications in young individuals with type 1 diabetes: results from the Diabetes Incidence Study in Sweden (DISS) and the National Diabetes Registry of Sweden (NDR) Diabetologia, Vol. 69, p. 50-58 (Article in journal) https://dx.doi.org/10.1007/s00125-025-06561-w

2024

Hans Arnqvist, Johnny Ludvigsson, Maria Nordwall (2024) Early increase in HbA1c trajectory predicts development of severe microangiopathy in patients with type 1 diabetes: the VISS study BMJ Open Diabetes Research & Care, Vol. 12, Article e003917 (Article in journal) https://dx.doi.org/10.1136/bmjdrc-2023-003917

2023

Hans Arnqvist, Per Leandersson, Anna Spångeus (2023) Vitamin D status in longstanding type 1 diabetes and controls. Association with upper extremity impairments Upsala Journal of Medical Sciences, Vol. 128 (Article in journal) https://dx.doi.org/10.48101/ujms.v128.9888

News

Organisation